{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:58:51Z","timestamp":1792195131432,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC 1168194"],"award-info":[{"award-number":["NHMRC 1168194"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40271-023-00635-w","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T23:28:44Z","timestamp":1687562924000},"page":"497-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma\u2014A Discrete Choice Experiment"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-0382","authenticated-orcid":false,"given":"Ann","family":"Livingstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-7540","authenticated-orcid":false,"given":"Kirsten","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-0572","authenticated-orcid":false,"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"20","key":"635_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"635_CR2","unstructured":"World Health Organization. Global Cancer Observatory 2020. International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/. Accessed 10 Jan 2022"},{"key":"635_CR3","unstructured":"Australian Institute of Health and Welfare [AIHW]. Cancer in Australia. Accessed\u00a010 Oct 2022.\u00a0https:\/\/www.aihw.gov.au\/getmedia\/0ea708eb-dd6e-4499-9080-1cc7b5990e64\/aihw-can-144.pdf.aspx?inline=true"},{"issue":"9","key":"635_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"issue":"16","key":"635_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"6","key":"635_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"key":"635_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-021-00507-1","author":"A Livingstone","year":"2021","unstructured":"Livingstone A, Milne D, Dempsey K, et al. Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners. Patient. 2021. https:\/\/doi.org\/10.1007\/s40271-021-00507-1.","journal-title":"Patient"},{"issue":"1","key":"635_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1186\/s12885-021-08756-x","volume":"21","author":"AJ Rodriguez-Acevedo","year":"2021","unstructured":"Rodriguez-Acevedo AJ, Chan RJ, Olsen CM, Pandeya N, Whiteman DC, Gordon LG. Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia. BMC Cancer. 2021;21(1):1055. https:\/\/doi.org\/10.1186\/s12885-021-08756-x.","journal-title":"BMC Cancer"},{"key":"635_CR9","unstructured":"Medical Device Innovation Consortium [MDIC]. Patient Centered Benefit-Risk Project Report: A Framework for Incorporating Information on Patient Preferences Regarding Benefit and Risk into Regulatory Assessments of New Medical Technology.\u00a0Accessed\u00a010 Oct 2022.\u00a0https:\/\/www.fda.gov\/media\/95591\/download."},{"key":"635_CR10","unstructured":"European Medicines Agency. Regulatory and methodological standards to improve benefit-risk evaluation of medicines. 2014.\u00a010 Oct 2022.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/report\/regulatory-methodological-standards-improve-benefit-risk-evaluation-medicines-workshop-report_en.pdf."},{"issue":"9","key":"635_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902. https:\/\/doi.org\/10.1007\/s40273-014-0170-x.","journal-title":"Pharmacoeconomics"},{"key":"635_CR12","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753930","volume-title":"Discrete choice methods with simulation","author":"K Train","year":"2003","unstructured":"Train K. Discrete choice methods with simulation. Cambridge University Press; 2003."},{"issue":"9","key":"635_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/MLR.0b013e31829faffd","volume":"51","author":"YN Wong","year":"2013","unstructured":"Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients\u2019 trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care. 2013;51(9):838\u201345. https:\/\/doi.org\/10.1097\/MLR.0b013e31829faffd.","journal-title":"Med Care"},{"key":"635_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5753-3","volume-title":"Using discrete choice experiments to value health and health care","author":"M Ryan","year":"2008","unstructured":"Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Springer; 2008."},{"key":"635_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health. 2011;14:403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value in Health"},{"key":"635_CR16","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781316136232","volume-title":"Applied choice analysis","author":"DA Hensher","year":"2015","unstructured":"Hensher DA, Rose JM, Greene WH. Applied choice analysis. 2nd ed. Cambridge University Press; 2015.","edition":"2"},{"issue":"8","key":"635_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201377. https:\/\/doi.org\/10.2165\/00019053-200826080-00004.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"635_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health."},{"issue":"1","key":"635_CR19","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1097\/NCC.0000000000000557","volume":"42","author":"FX Liu","year":"2019","unstructured":"Liu FX, Witt EA, Ebbinghaus S, DiBonaventura BG, Basurto E, Joseph RW. Patient and oncology nurse preferences for the treatment options in advanced melanoma: a discrete choice experiment. Cancer Nurs Jan\/Feb. 2019;42(1):E52\u20139. https:\/\/doi.org\/10.1097\/NCC.0000000000000557.","journal-title":"Cancer Nurs. Jan\/Feb"},{"key":"635_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/PPA.S140226","volume":"11","author":"FX Liu","year":"2017","unstructured":"Liu FX, Witt EA, Ebbinghaus S, et al. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adherence. 2017;11:1389\u201399. https:\/\/doi.org\/10.2147\/PPA.S140226.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"635_CR21","doi-asserted-by":"publisher","first-page":"adv0083","DOI":"10.2340\/00015555-3422","volume":"100","author":"J Weilandt","year":"2020","unstructured":"Weilandt J, Diehl K, Schaarschmidt ML, et al. Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment. Acta Derm Venereol. 2020;100(6):adv0083. https:\/\/doi.org\/10.2340\/00015555-3422.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"635_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1245\/s10434-019-07963-y","volume":"27","author":"A Livingstone","year":"2020","unstructured":"Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2020;27(2):571\u201384. https:\/\/doi.org\/10.1245\/s10434-019-07963-y.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"635_CR23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/fon-2018-0871","volume":"15","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019;15(11):1255\u201368. https:\/\/doi.org\/10.2217\/fon-2018-0871.","journal-title":"Future Oncol"},{"issue":"6","key":"635_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/CMR.0000000000000572","volume":"29","author":"DD Stenehjem","year":"2019","unstructured":"Stenehjem DD, Au TH, Ngorsuraches S, et al. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. 2019;29(6):626\u201334. https:\/\/doi.org\/10.1097\/CMR.0000000000000572.","journal-title":"Melanoma Res"},{"key":"635_CR25","unstructured":"Huynh E, Rose J, Lambides M, Cong K, Herawati L, Cuore MD. Preferences for advanced melanoma immuno-oncology treatments. In: Presented at: Pigment Cell and Melanoma Research; 2018."},{"issue":"1","key":"635_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4236\/jct.2017.81004","volume":"8","author":"K Beusterien","year":"2017","unstructured":"Beusterien K, Middleton MR, Wang PF, et al. Patient and physician preferences for treating adjuvant melanoma: a discrete choice experiment. J Cancer Ther. 2017;8(1):37\u201350. https:\/\/doi.org\/10.4236\/jct.2017.81004.","journal-title":"J Cancer Ther"},{"key":"635_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219905","author":"M Trapero-Bertran","year":"2019","unstructured":"Trapero-Bertran M, Rodriguez-Martin B, Lopez-Bastida J. What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review PLoS One. 2019. https:\/\/doi.org\/10.1371\/journal.pone.0219905.","journal-title":"A systematic literature review. PLoS One."},{"key":"635_CR28","unstructured":"Australian Government. Pharmaceutical Benefits Scheme - Nivolumab. Webpage. Australian Government. 20 August 2020. https:\/\/www.pbs.gov.au\/medicine\/item\/10745M-10748Q-10764M-10775D-11143L-11150W-11152Y-11153B-11157F-11158G-11159H-11160J-11411N-11425H-11434T-11435W-11532Y-11543M-11626X-11627Y-11631E-11635J-11636K-11642R-11900H-11906P. Accessed 20 Aug 2020."},{"key":"635_CR29","unstructured":"Australian Government. Pharmaceutical Benefits Scheme - Pembrolizumab. Webpage. Australian Government. 10 September 2020. https:\/\/www.pbs.gov.au\/medicine\/item\/10424P-10436G-10475H-10493G-11330H-11352L-11492W-11494Y-11632F-11646Y-12119W-12120X-12121Y-12122B-12123C-12124D-12125E-12126F-12127G-12128H-12129J-12130K. Accessed 10 Sep 2020."},{"key":"635_CR30","volume-title":"The think aloud method: a practical approach to modelling cognitive processes","author":"M van Someren","year":"1993","unstructured":"van Someren M, Barnard Y, Sandberg J. The think aloud method: a practical approach to modelling cognitive processes. Academic Press; 1993."},{"issue":"1","key":"635_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health Jan-Feb. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health. Jan-Feb"},{"issue":"3","key":"635_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40258-016-0232-7","volume":"14","author":"A Muhlbacher","year":"2016","unstructured":"Muhlbacher A, Johnson FR. Choice experiments to quantify preferences for health and healthcare: state of the practice. Appl Health Econ Health Policy. 2016;14(3):253\u201366. https:\/\/doi.org\/10.1007\/s40258-016-0232-7.","journal-title":"Appl Health Econ Health Policy"},{"key":"635_CR33","unstructured":"Green WH. NLOGIT Version 6 reference guide. Econometric Software Inc. Accessed 6 Sept 2021."},{"issue":"2","key":"635_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"key":"635_CR35","volume-title":"Economic analysis in health care","author":"S Morris","year":"2012","unstructured":"Morris S, Devlin N, Parkin D, Spencer A. Economic analysis in health care. 2nd ed. Berlin: Wiley; 2012.","edition":"2"},{"key":"635_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocm.2017.03.001","volume":"23","author":"S Hess","year":"2017","unstructured":"Hess S, Train K. Correlation and scale in mixed logit models. Journal of Choice Modelling. 2017;23:1\u20138.","journal-title":"Journal of Choice Modelling."},{"issue":"8","key":"635_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jval.2020.04.1831","volume":"23","author":"DJ Mott","year":"2020","unstructured":"Mott DJ, Chami N, Tervonen T. Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences. Value Health. 2020;23(8):979\u201384.","journal-title":"Value Health."},{"key":"635_CR38","volume-title":"Microeconomic analysis","author":"H Varian","year":"1992","unstructured":"Varian H. Microeconomic analysis. W.W. Norton; 1992."},{"issue":"12","key":"635_CR39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ejca.2015.05.022","volume":"51","author":"P Blinman","year":"2015","unstructured":"Blinman P, Hughes B, Crombie C, et al. Patients\u2019 and doctors\u2019 preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile? Eur J Cancer. 2015;51(12):1529\u201337.","journal-title":"Eur J Cancer"},{"issue":"3","key":"635_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<267::AID-HEC511>3.0.CO;2-H","volume":"9","author":"G Salkeld","year":"2000","unstructured":"Salkeld G, Ryan M, Short L. The veil of experience. Do consumers prefer what they know best? Health Econ. 2000;9(3):267\u201370.","journal-title":"Health Econ"},{"issue":"2","key":"635_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/1475-6773.12712","volume":"53","author":"EC Norton","year":"2018","unstructured":"Norton EC, Dowd BE. Log odds and the interpretation of logit models. Health Serv Res. 2018;53(2):859\u201378. https:\/\/doi.org\/10.1111\/1475-6773.12712.","journal-title":"Health Serv Res"},{"issue":"9","key":"635_CR42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/hec.870","volume":"13","author":"E Lancsar","year":"2004","unstructured":"Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Econ. 2004;13(9):901\u20137. https:\/\/doi.org\/10.1002\/hec.870.","journal-title":"Health Econ"},{"issue":"19","key":"635_CR43","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med"},{"key":"635_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.876","author":"F Johnson","year":"2018","unstructured":"Johnson F, Yang J-C, Reed S. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2018. https:\/\/doi.org\/10.1016\/j.jval.2018.07.876.","journal-title":"Value Health."},{"issue":"19","key":"635_CR45","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"5","key":"635_CR46","doi-asserted-by":"publisher","first-page":"S1283","DOI":"10.1016\/annonc\/annonc741","volume":"32(LBA3_PR)","author":"J Luke","year":"2021","unstructured":"Luke J, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Ann Oncol. 2021;32(LBA3_PR)(5):S1283\u2013346. https:\/\/doi.org\/10.1016\/annonc\/annonc741.","journal-title":"Ann Oncol"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-023-00635-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-023-00635-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-023-00635-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T07:58:07Z","timestamp":1691481487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-023-00635-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s40271-023-00635-w","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"18 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this work was provided by the Australian National Health and Medical Research Council (NHMRC 1168194), Cancer Institute New South Wales, Melanoma Institute Australia, Sydney Catalyst, Nicholas and Helen Moore, and the University of Sydney.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AL, RLM and KH have no financial disclosures. AMM served on BMS, MSD, Novartis, Roche, Pierre-Fabre and QBiotics advisory boards. GVL is a consultant advisor for Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Hexel AG, Highlight Therapeutics SL, MSD, Novartis, Pierre-Fabre, Provectus, QBiotics, Regeneron Pharmaceuticals and Specialised Therapeutics Australia. MRS received institutional research support from Amgen, Astellas, AstraZeneca, Bayer, Bionomics, BMS, Celgene, Medivation, MSD, Pfizer, Roche, Sanofi and Tilray but did not sit on any advisory boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The Sydney Local Health District Human Research Ethics Committee (HREC\/18\/RPAH\/736) granted ethics approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written consent; the Declaration of Helsinki underpinned this study [].","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"De-identified datasets used and analysed during the current study may be available from the corresponding author if the request falls within the project\u2019s ethics approval.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"AL: conceptualisation, methodology, resources, writing \u2013 original draft preparation; KH: supervision, assistance with DCE methodology, writing, critical review\/editing; AMM: supervision, assistance with participant recruitment, writing, critical review\/editing, GVL: assistance with participant recruitment, critical review\/editing; MRS: supervision, writing, critical review\/editing, RLM: conceptualisation, supervision, assistance with DCE methodology, resources, writing, critical review\/editing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}